Key Takeaway: Cognition Therapeutics announced that results from their Phase 2 SHINE study of CT1812 in patients with mild-to-moderate Alzheimer's disease have been accepted for presentation at the Alzheimer's Association International Conference (AAIC). This acceptance underscores the importance of their research in addressing Alzheimer's disease.
Price reaction · baseline $1.67 (2024-07-01 close) · hit pre-market · clean, no other CGTX news in the window
day 0 close
+9%
day 1
+6%
day 3 · peak
+12.6%
Market Sentiment Analysis
POSITIVE FACTORS
Results from the Phase 2 SHINE study show promise for CT1812.
The study focuses on mild-to-moderate Alzheimer's disease.
Acceptance for presentation at AAIC highlights the study's significance.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
Frequently Asked Questions
What is the SHINE study?
The SHINE study is a Phase 2 clinical trial evaluating CT1812 in Alzheimer's patients.
Where will the study results be presented?
The results will be presented at the Alzheimer's Association International Conference (AAIC).